FindTrial
Sign In

HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518022-33-00
Acronym
Uni-Koeln-1762
Enrollment
1320
Registered
2024-10-31
Start date
2016-07-15
Completion date
2024-12-01
Last updated
2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Stage of Hodgkin Lymphoma

Brief summary

Randomized main study: Treatment-related morbidity (TRMB), Randomized main study: Progression-free survival (PFS), Cohort of older patients: Complete remission (CR) rate after chemotherapy

Detailed description

Randomized main study: Tumor response (CR rate), Randomized main study: Overall survival (OS), Randomized main study: Infertility rate at 1 year, Randomized main study: Second malignancies, Randomized main study: Quality of life (QoL), Randomized main study: Frequency of adverse events, Randomized main study: Therapy adherence, Randomized main study: Event-free Survival (EFS), Cohort of older Patients: TRMB, Cohort of older patients: PFS, Cohort of older patients: OS, Cohort of older patients: Time to progression (PFSHL) and HL-specific survival (OSHL)

Interventions

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion
DRUGDOXORUBICIN HYDROCHLORIDE
DRUGDEXAMETHASONE
DRUGPROCARBAZINE HYDROCHLORIDE
DRUGBLEOMYCIN SULFATE
DRUGVINCRISTINE SULFATE
DRUGPREDNISONE
DRUGDACARBAZINE
DRUGETOPOSIDE PHOSPHATE
DRUGCYCLOPHOSPHAMIDE MONOHYDRATE
DRUGETOPOSIDE

Sponsors

University Of Cologne
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Randomized main study: Treatment-related morbidity (TRMB), Randomized main study: Progression-free survival (PFS), Cohort of older patients: Complete remission (CR) rate after chemotherapy—

Secondary

MeasureTime frame
Randomized main study: Tumor response (CR rate), Randomized main study: Overall survival (OS), Randomized main study: Infertility rate at 1 year, Randomized main study: Second malignancies, Randomized main study: Quality of life (QoL), Randomized main study: Frequency of adverse events, Randomized main study: Therapy adherence, Randomized main study: Event-free Survival (EFS), Cohort of older Patients: TRMB, Cohort of older patients: PFS, Cohort of older patients: OS, Cohort of older patients: Time to progression (PFSHL) and HL-specific survival (OSHL)—

Countries

Austria, Denmark, Germany, Netherlands, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026